Docoh
Loading...

IONS Ionis Pharmaceuticals

188 patents

Page 3 of 10
APP
Utility
Selective Antisense Compounds and Uses Thereof
20 May 21
The present invention provides oligomeric compounds.
Punit P. Seth, Michael Oestergaard, Eric E. Swayze
Filed: 30 Jun 20
APP
Utility
Compounds and Methods for Reducing Spdef Expression
13 May 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SPDEF RNA in a cell or subject, and in certain instances reducing the amount of SPDEF protein in a cell or subject.
Susan M. Freier, Huynh-Hoa Bui, Shuling Guo, Jeffrey R. Crosby
Filed: 12 Jan 21
APP
Utility
Modulation of Huntingtin Expression
13 May 21
Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal.
Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
Filed: 12 Oct 20
GRANT
Utility
Modulators of PCSK9 expression
11 May 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
Filed: 1 Nov 19
APP
Utility
Compositions and Methods
6 May 21
Provided herein are oligomeric compounds with conjugate groups.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 24 Jun 20
APP
Utility
Methods of Modulating Antisense Activity
6 May 21
Disclosed herein are methods for increasing antisense oligonucleotide activity in a cell by modulating autophagy of the cell.
Joseph OCHABA, JR., Mariam AGHAJAN
Filed: 4 Apr 19
APP
Utility
Modulators of YAP1 Expression
29 Apr 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
Filed: 31 Jan 20
APP
Utility
Modulation of Transthyretin Expression
1 Apr 21
Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal.
Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
Filed: 1 Jun 20
GRANT
Utility
Methods of modulating KEAP1
30 Mar 21
Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal.
Richard Lee, Jeffrey R. Crosby
Filed: 16 Mar 17
APP
Utility
Modulation of Alpha Synuclein Expression
25 Mar 21
Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression.
Susan M. Freier
Filed: 17 Sep 20
APP
Utility
Modulation of Frataxin Expression
25 Mar 21
Certain embodiments are directed to methods and compounds for increasing FXN.
Frank RIGO, Thazha P. PRAKASH, David COREY
Filed: 21 Dec 18
APP
Utility
Compounds and Methods for Reducing Fxi Expression
25 Mar 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject.
Huynh-Hoa Bui
Filed: 6 Nov 20
APP
Utility
COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
25 Mar 21
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)].
Thazha P. PRAKASH, Punit P. SETH, Eric E. SWAYZE, Mark J. GRAHAM
Filed: 1 Oct 20
GRANT
Utility
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
23 Mar 21
Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal.
Eric E. Swayze, Susan M. Freier
Filed: 23 Oct 18
APP
Utility
Modulators of PCSK9 Expression
18 Mar 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
Filed: 20 Nov 20
APP
Utility
Antisense Oligonucleotide Compositions
18 Mar 21
The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity.
Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
Filed: 9 Jun 20
APP
Utility
Modulators of APOL1 Expression
18 Mar 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
Susan M. FREIER
Filed: 18 Sep 20
APP
Utility
Modulators of PNPLA3 Expression
18 Mar 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting PNPLA3 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PNPLA3.
Susan M. FREIER, Huynh-Hoa BUI
Filed: 22 Jul 20
GRANT
Reissue
Modulation of androgen receptor expression
9 Mar 21
Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
Filed: 13 Feb 19
APP
Utility
Conjugated Antisense Compounds and Their Use
25 Feb 21
Provided herein are oligomeric compounds comprising a modified oligonucleotide and a conjugate group for modulating the amount or activity of a target nucleic acid in extra hepatic tissues and extra hepatic cells.
Thazha P. Prakash, Richard Lee, Punit P. Seth, Eric E. Swayze, Frank Rigo, Michael Oestergaard
Filed: 26 Sep 16
Patents are sorted by USPTO publication date, most recent first